Financhill
Back

Viking Therapeutics Quote, Financials, Valuation and Earnings

My #1 Coin is...

All the details are on the next page.
Buy
61

VKTX
Viking Therapeutics

Last Price:
74.28
Seasonality Move:
18.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Unlock the Secret to Earning Monthly Income!

Limited spots act swiftly

Viking Therapeutics Price Quote

$74.28
+5.42 (+7.87%)
(Updated: April 26, 2024 at 6:55 PM ET)

Viking Therapeutics Key Stats

Buy
61
Viking Therapeutics (VKTX) is a Buy

Day range:
$62.56 - $69.17
52-week range:
$8.28 - $99.41
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
8.13%

Volume:
3.5M
Avg. volume:
3.9M
1-year change:
246.38%
Market cap:
$7.6B
Revenue:
$0
EPS:
$-0.93

How Much Does Viking Therapeutics Make?

Data Unavailable

Is Viking Therapeutics Growing As A Company?

Data Unavailable

Viking Therapeutics Stock Price Performance

What Is Viking Therapeutics 52-Week High & Low?

Viking Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Viking Therapeutics?

Is Viking Therapeutics Cash Flow Positive?

  • What Is VKTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$54.9M
  • What Is Viking Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $873.2M
  • What Is Viking Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$641.1M

Viking Therapeutics Return On Invested Capital

Data Unavailable

Viking Therapeutics Earnings Date & Stock Price

Viking Therapeutics Competitors

Viking Therapeutics Dividend Yield

Data Unavailable

Viking Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 6.03%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 108.44
Upside from Last Price: 57.48%

Major Shareholders

  • How many VKTX shares are owned by institutional investors?
    138.1M VKTX shares are owned by institutional investors
  • How many VKTX shares are owned by insiders?
    4.3M VKTX shares are owned by insiders